Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

Lieping Chen, Elaine Kinney Thomas, Shiu Lok Hu, Ingegerd Hellström, Karl Erik Hellström

Research output: Contribution to journalArticle

Abstract

It has been speculated that immunological mechanisms play an important role in the control of carcinomas associated with human papillomavirus (HPV), such as cervical cancers. We have now demonstrated that immunization of C3H/HeN mice by syngeneic nontumorigenic fibroblast-like cells that contain the transfected HPV-16 E7 gene conferred protection against transplanted cells from a HPV-16 E7-positive syngeneic tumor. This protection was HPV-16 E7-specific and was mediated by CDS+ lymphocytes, which presumably were cytotoxic T lymphocytes. These results indicate that tumor cells containing HPV-16 E7, either as a result of transfection, as in our studies, or naturally, as occurs in many human carcinomas, can induce a tumor-specific rejection response and serve as targets for such a response. The system described here provides an animal model to further study immune responses to HPV-associated malignancies and to test the efficacy of anti-HPV vaccines toward the therapy and prevention of such tumors.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume88
Issue number1
StatePublished - Jan 1 1991
Externally publishedYes

Keywords

  • Immunoprevention
  • Immunosurveillance
  • Immunotherapy
  • Tumor immunity

ASJC Scopus subject areas

  • General
  • Genetics

Fingerprint Dive into the research topics of 'Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen'. Together they form a unique fingerprint.

  • Cite this